Literature DB >> 27799295

The M1 Muscarinic Receptor Antagonist VU0255035 Delays the Development of Status Epilepticus after Organophosphate Exposure and Prevents Hyperexcitability in the Basolateral Amygdala.

Steven L Miller1, Vassiliki Aroniadou-Anderjaska1, Volodymyr I Pidoplichko1, Taiza H Figueiredo1, James P Apland1, Jishnu K S Krishnan1, Maria F M Braga2.   

Abstract

Exposure to organophosphorus toxins induces seizures that progress to status epilepticus (SE), which can cause brain damage or death. Seizures are generated by hyperstimulation of muscarinic receptors, subsequent to inhibition of acetylcholinesterase; this is followed by glutamatergic hyperactivity, which sustains and reinforces seizure activity. It has been unclear which muscarinic receptor subtypes are involved in seizure initiation and the development of SE in the early phases after exposure. Here, we show that pretreatment of rats with the selective M1 receptor antagonist, VU0255035 [N-(3-oxo-3-(4-(pyridine-4-yl)piperazin-1-yl)propyl)-benzo[c][1,2,5]thiadiazole-4 sulfonamide], significantly suppressed seizure severity and prevented the development of SE for about 40 minutes after exposure to paraoxon or soman, suggesting an important role of the M1 receptor in the early phases of seizure generation. In addition, in in vitro brain slices of the basolateral amygdala (a brain region that plays a key role in seizure initiation after nerve agent exposure), VU0255035 blocked the effects produced by bath application of paraoxon-namely, a brief barrage of spontaneous inhibitory postsynaptic currents, followed by a significant increase in the ratio of the total charge transferred by spontaneous excitatory postsynaptic currents over that of the inhibitory postsynaptic currents. Furthermore, paraoxon enhanced the hyperpolarization-activated cation current Ih in basolateral amygdala principal cells, which could be one of the mechanisms underlying the increased glutamatergic activity, an effect that was also blocked in the presence of VU0255035. Thus, selective M1 antagonists may be an efficacious pretreatment in contexts in which there is risk for exposure to organophosphates, as these antagonists will delay the development of SE long enough for medical assistance to arrive.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27799295      PMCID: PMC5193080          DOI: 10.1124/jpet.116.236125

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  56 in total

1.  Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice.

Authors:  Stephan G Anagnostaras; Geoffrey G Murphy; Susan E Hamilton; Scott L Mitchell; Nancy P Rahnama; Neil M Nathanson; Alcino J Silva
Journal:  Nat Neurosci       Date:  2003-01       Impact factor: 24.884

Review 2.  Comparison of status epilepticus models induced by pilocarpine and nerve agents - a systematic review of the underlying aetiology and adopted therapeutic approaches.

Authors:  F R Tang; W K Loke; E A Ling
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 3.  Muscarinic acetylcholine receptors: novel opportunities for drug development.

Authors:  Andrew C Kruse; Brian K Kobilka; Dinesh Gautam; Patrick M Sexton; Arthur Christopoulos; Jürgen Wess
Journal:  Nat Rev Drug Discov       Date:  2014-06-06       Impact factor: 84.694

4.  Anticonvulsants for poisoning by the organophosphorus compound soman: pharmacological mechanisms.

Authors:  T M Shih; T A Koviak; B R Capacio
Journal:  Neurosci Biobehav Rev       Date:  1991       Impact factor: 8.989

5.  N-[3H]methylscopolamine labeling of non-M1, non-M2 muscarinic receptor binding sites in rat brain.

Authors:  T D Smith; S J Annis; F J Ehlert; F M Leslie
Journal:  J Pharmacol Exp Ther       Date:  1991-03       Impact factor: 4.030

6.  Primary brain targets of nerve agents: the role of the amygdala in comparison to the hippocampus.

Authors:  Vassiliki Aroniadou-Anderjaska; Taiza H Figueiredo; James P Apland; Felicia Qashu; Maria F M Braga
Journal:  Neurotoxicology       Date:  2009-07-08       Impact factor: 4.294

7.  ASIC1a activation enhances inhibition in the basolateral amygdala and reduces anxiety.

Authors:  Volodymyr I Pidoplichko; Vassiliki Aroniadou-Anderjaska; Eric M Prager; Taiza H Figueiredo; Camila P Almeida-Suhett; Steven L Miller; Maria F M Braga
Journal:  J Neurosci       Date:  2014-02-26       Impact factor: 6.167

8.  Muscarinic cholinergic receptor subtypes in the rat brain. I. Quantitative autoradiographic studies.

Authors:  R Cortés; J M Palacios
Journal:  Brain Res       Date:  1986-01-08       Impact factor: 3.252

9.  Direct autoradiographic determination of M1 and M2 muscarinic acetylcholine receptor distribution in the rat brain: relation to cholinergic nuclei and projections.

Authors:  D G Spencer; E Horváth; J Traber
Journal:  Brain Res       Date:  1986-08-13       Impact factor: 3.252

10.  Atropine and/or diazepam therapy protects against soman-induced neural and cardiac pathology.

Authors:  J H McDonough; N K Jaax; R A Crowley; M Z Mays; H E Modrow
Journal:  Fundam Appl Toxicol       Date:  1989-08
View more
  8 in total

1.  Inducible nitric oxide synthase inhibitor, 1400W, mitigates DFP-induced long-term neurotoxicity in the rat model.

Authors:  Marson Putra; Shaunik Sharma; Meghan Gage; Grace Gasser; Andy Hinojo-Perez; Ashley Olson; Adriana Gregory-Flores; Sreekanth Puttachary; Chong Wang; Vellareddy Anantharam; Thimmasettappa Thippeswamy
Journal:  Neurobiol Dis       Date:  2019-03-30       Impact factor: 5.996

2.  The Firing of Theta State-Related Septal Cholinergic Neurons Disrupt Hippocampal Ripple Oscillations via Muscarinic Receptors.

Authors:  Xiaoyu Ma; Yiyao Zhang; Lina Wang; Na Li; Edi Barkai; Xiaohui Zhang; Longnian Lin; Jiamin Xu
Journal:  J Neurosci       Date:  2020-04-07       Impact factor: 6.167

3.  Full Protection Against Soman-Induced Seizures and Brain Damage by LY293558 and Caramiphen Combination Treatment in Adult Rats.

Authors:  James P Apland; Vassiliki Aroniadou-Anderjaska; Taiza H Figueiredo; Marcio De Araujo Furtado; Maria F M Braga
Journal:  Neurotox Res       Date:  2018-04-30       Impact factor: 3.911

4.  Novel long-acting antagonists of muscarinic ACh receptors.

Authors:  Alena Randáková; Vladimír Rudajev; Vladimír Doležal; John Boulos; Jan Jakubík
Journal:  Br J Pharmacol       Date:  2018-04-14       Impact factor: 8.739

Review 5.  Cholinergic Signaling, Neural Excitability, and Epilepsy.

Authors:  Yu Wang; Bei Tan; Yi Wang; Zhong Chen
Journal:  Molecules       Date:  2021-04-13       Impact factor: 4.411

6.  Antiseizure and Neuroprotective Efficacy of Midazolam in Comparison with Tezampanel (LY293558) against Soman-Induced Status Epilepticus.

Authors:  Taiza H Figueiredo; Vassiliki Aroniadou-Anderjaska; Volodymyr I Pidoplichko; James P Apland; Maria F M Braga
Journal:  Toxics       Date:  2022-07-22

7.  Mechanisms of organophosphate neurotoxicity.

Authors:  Yi-Hua Tsai; Pamela J Lein
Journal:  Curr Opin Toxicol       Date:  2021-04-30

Review 8.  Crosstalk between the M1 muscarinic acetylcholine receptor and the endocannabinoid system: A relevance for Alzheimer's disease?

Authors:  Karen J Thompson; Andrew B Tobin
Journal:  Cell Signal       Date:  2020-01-21       Impact factor: 4.315

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.